IACS-010759,1570496-34-2

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

IACS-010759

CAS No. : 1570496-34-2

MCE 国际站：IACS-010759

产品活性：IACS-010759 是一种口服有效的线粒体氧化磷酸化复合物 I (OXPHOS) 抑制剂。IACS-010759 在依赖 OXPHOS 的脑癌和急性髓性白血病 (AML) 模型中抑制增殖并诱导细胞凋亡。IACS-010759 具有用于复发/难治性 AML 和实体瘤研究的潜力。

研究领域：Metabolic Enzyme/Protease  |  Apoptosis

作用靶点：Mitochondrial Metabolism  |  Apoptosis

In Vitro: IACS-010759 (10, 30, 100?nM; for 4 or 5 days) reduces viability and induces apoptosis in primary AML.
?IACS-010759 (0.001, 0.01, 0.1, 1, 10, 100, 1000 nM; 72 hurs) robustly inhibits both OCR and galactose-dependent H460 cell viability and has nearly identical IC₅₀ values of 1.4?nM.
?IACS-010759 is similarly active in mouse (average IC₅₀?=?5.6?nM), rat (IC₅₀?=?12.2?nM), and cynomolgus monkey (IC50?=?8.7?nM) cell lines.
?IACS-010759 (0.01-10 μM) yieldes a maximal reduction of growth of?>?50% in the majority of cancer cell lines (24 of 30 pancreatic (PDAC), 19 of 20 ovarian, 13 of 16 triple-negative breast (TNBC), 8 of 10 non-small-cell lung (NSCLC)) and a subset (11of 30 PDAC, 10 of 20 ovarian, 5 of 16 TNBC, 2 of 10 NSCLC) exhibited?>?100% growth inhibition.

In Vivo: IACS-010759 (5, 10, 25?mg/kg/day; oral; for 21 d) results in tumor regression with minimal body weight loss at the 5 or 10?mg/kg dose in mice bearing NB-1 (PGD-null) subcutaneous xenografts. IACS-010759 at the 25?mg/kg dose is not tolerated.
?IACS-010759 HCl (10?mg/kg; orally; QD (daily) or QD×5 (5 d on/2 d off); for 35 d) increases median survival from 28 d to longer than 60 d, whereas less-frequent dosing schedules (Q2D or Q3D) enhances survival to a lesser extent.
?IACS-010759 (0.3?mg/kg for iv; 1?mg/kg for oral) has low plasma clearance with a high volume of distribution, resulting in a prolonged terminal half-life (>24?h).

相关产品：Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Apoptosis Compound Library  |  Metabolism/Protease Compound Library  |  Stem Cell Signaling Compound Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  Anti-Aging Compound Library  |  Reprogramming Compound Library  |  Orally Active Compound Library  |  Glutamine Metabolism Compound Library  |  Anti-Lung Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  Anti-Cancer Metabolism Compound Library  |  Anti-Parkinson's Disease Compound Library  |  Neurodegenerative Disease-related Compound Library  |  Mitochondria-Targeted Compound Library  |  Glucose Metabolism Compound Library  |  Cuproptosis Compound Library  |  Cancer Stem Cells Compound Library  |  Heterocyclic Compound Library  |  Mitochondrial Protection Compound Library  |  Cell Death Library  |  MG-132  |  Doxorubicin hydrochloride  |  Bafilomycin A1  |  LY294002  |  Tamoxifen  |  Paclitaxel  |  Y-27632  |  Acetylcysteine  |  Angiotensin II human  |  2-Deoxy-D-glucose  |  Staurosporine  |  SB-431542  |  Actinomycin D  |  Deferoxamine mesylate  |  Bortezomib  |  5-Fluorouracil  |  Trametinib  |  Sorafenib  |  Oxaliplatin  |  Gemcitabine  |  Temozolomide  |  Rotenone  |  Mdivi-1  |  Elesclomol  |  Ruxolitinib  |  Decitabine  |  SP600125  |  MK-2206 dihydrochloride  |  Etoposide  |  Monomethyl auristatin E

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds